Cytomegalovirus vaccine live attenuated - MedImmune Vaccines

Drug Profile

Cytomegalovirus vaccine live attenuated - MedImmune Vaccines

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator MedImmune Vaccines
  • Class Cytomegalovirus vaccines; Viruses
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 29 Sep 2004 Discontinued - Phase-I for Cytomegalovirus infections treatment in USA (Injection)
  • 31 Dec 2002 MedImmune has completed a phase I trial in Cytomegalovirus infections in the US
  • 03 Dec 2001 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top